Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel poliglumex

Drug Profile

Paclitaxel poliglumex

Alternative Names: CHC 12103; CT-2103; Opaxio; PG - paclitaxel CTI BioPharma; PG-TXL; Poly(L-glutamic acid)-paclitaxel conjugate; Polyglutamate - Taxol; Polyglutamate-paclitaxel conjugate; Polyglutamic acid paclitaxel; PPX; Xyotax™

Latest Information Update: 31 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PG-TXL Company; University of Texas M. D. Anderson Cancer Center
  • Developer Brown University; CTI BioPharma; Gynecologic Oncology Group; National Cancer Institute (USA); State University of New York
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Taxanes
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 13 Mar 2019 Discontinued - Phase-I/II for Head and neck cancer (Combination therapy, Late-stage disease) in USA (IV)
  • 13 Mar 2019 Discontinued - Phase-II for Glioblastoma (First-line therapy) in USA (IV)
  • 13 Mar 2019 Discontinued - Phase-II for Glioma (Combination therapy, First-line therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top